EP1296702A4 - NEUROPROTECTIVE PEPTIDES - Google Patents

NEUROPROTECTIVE PEPTIDES

Info

Publication number
EP1296702A4
EP1296702A4 EP01941562A EP01941562A EP1296702A4 EP 1296702 A4 EP1296702 A4 EP 1296702A4 EP 01941562 A EP01941562 A EP 01941562A EP 01941562 A EP01941562 A EP 01941562A EP 1296702 A4 EP1296702 A4 EP 1296702A4
Authority
EP
European Patent Office
Prior art keywords
neuroprotective peptides
neuroprotective
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01941562A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1296702A1 (en
Inventor
Virginia Smith-Swintosky
Michael Renzi
Carlos Plata-Salaman
Linda Jolliffe
Francis Farrell
Dana L Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22771463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1296702(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of EP1296702A1 publication Critical patent/EP1296702A1/en
Publication of EP1296702A4 publication Critical patent/EP1296702A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
EP01941562A 2000-05-26 2001-05-23 NEUROPROTECTIVE PEPTIDES Withdrawn EP1296702A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20765400P 2000-05-26 2000-05-26
US207654P 2000-05-26
PCT/US2001/016654 WO2001091780A1 (en) 2000-05-26 2001-05-23 Neuroprotective peptides

Publications (2)

Publication Number Publication Date
EP1296702A1 EP1296702A1 (en) 2003-04-02
EP1296702A4 true EP1296702A4 (en) 2005-05-11

Family

ID=22771463

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01941562A Withdrawn EP1296702A4 (en) 2000-05-26 2001-05-23 NEUROPROTECTIVE PEPTIDES

Country Status (11)

Country Link
EP (1) EP1296702A4 (enExample)
JP (1) JP2003534384A (enExample)
CN (1) CN1318084C (enExample)
AU (2) AU7490401A (enExample)
BR (1) BR0111182A (enExample)
CA (1) CA2410453A1 (enExample)
IL (1) IL153079A0 (enExample)
MX (1) MXPA02011727A (enExample)
NZ (1) NZ522924A (enExample)
WO (1) WO2001091780A1 (enExample)
ZA (1) ZA200210304B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE296350T1 (de) 1999-06-14 2005-06-15 Genentech Inc Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
EP1625156B1 (en) * 2003-05-12 2012-09-19 Affymax, Inc. Peptides that bind to the erythropoietin receptor
EP1626983B8 (en) 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
AU2004238870B8 (en) 2003-05-12 2010-04-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2007500218A (ja) 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッド ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP2275142A3 (en) 2006-06-30 2011-05-11 Andre Koltermann Conjugates for immunotherapy of cancer
EP2118127A4 (en) 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
SG10201604530SA (en) * 2008-01-22 2016-07-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8426402B2 (en) 2009-02-05 2013-04-23 Immunogen, Inc. Benzodiazepine derivatives
RU2410392C2 (ru) 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
IL279304B (en) * 2011-02-15 2022-07-01 Immunogen Inc Method for producing an indolinobenzodiazepine
KR20160052537A (ko) * 2013-07-17 2016-05-12 아라임 파마슈티칼즈, 인크. 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
TW202024117A (zh) 2018-09-14 2020-07-01 日商Ｅｐｏ醫藥股份有限公司 抗紅血球生成素受體胜肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0191780A1 *

Also Published As

Publication number Publication date
BR0111182A (pt) 2004-02-25
EP1296702A1 (en) 2003-04-02
CA2410453A1 (en) 2001-12-06
CN1452492A (zh) 2003-10-29
HK1058484A1 (zh) 2004-05-21
WO2001091780A1 (en) 2001-12-06
JP2003534384A (ja) 2003-11-18
MXPA02011727A (es) 2003-10-24
IL153079A0 (en) 2003-06-24
AU2001274904B2 (en) 2006-08-31
NZ522924A (en) 2004-12-24
CN1318084C (zh) 2007-05-30
AU7490401A (en) 2001-12-11
ZA200210304B (en) 2004-03-19

Similar Documents

Publication Publication Date Title
IL153079A0 (en) Neuroprotective peptides
GB0014870D0 (en) Peptides
IL146832A0 (en) Peptides
SI1294381T1 (sl) Neuroprotektivni 7-beta-hidroksi steroidi
GB0029777D0 (en) Peptides
AU6268901A (en) Oligopeptides
EP1147130A4 (en) ALPHA-conotoxin PEPTIDE
GB0001825D0 (en) Peptides
GB9903408D0 (en) Peptides
GB0007263D0 (en) Peptides
EP1323731A4 (en) NEW PEPTIDES
GB0018307D0 (en) Polypeptides
GB0001826D0 (en) Peptides
GB0021475D0 (en) Anti-aniogenic peptides
GB0007264D0 (en) Peptides
GB0010327D0 (en) Peptides
GB0113257D0 (en) Polypeptides
GB9928325D0 (en) Peptides
GB9907911D0 (en) Peptides
TJ20000630A (en) Photosensetive material
GB0029850D0 (en) Modifying material
GB0021877D0 (en) Novel peptide sequence
GB0017431D0 (en) Novel peptide sequence
GB0117737D0 (en) Modified peptides
GB0125372D0 (en) Modified peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050322

17Q First examination report despatched

Effective date: 20070330

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110615